Review
Oncology
Johanna C. Maedge, Andreas Stallmach, Lisa Kleebusch, Peter Schlattmann
Summary: Aspirin can improve the survival of patients with colorectal cancer, and PIK3CA mutation and high expression of PTGS2 are associated with longer survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Oncology
Xiaxia Man, Baogang Wang, Yuying Tan, Xiaolin Yang, Songling Zhang
Summary: The meta-analysis showed that there was no statistically significant association between aspirin use and mortality in women with ovarian cancer. The results were consistent for ovarian cancer-specific mortality and all-cause mortality. Stratified analyses indicated that aspirin use did not have a significant association with mortality risk in ovarian cancer patients, regardless of various factors. Funnel plots suggested a potential risk of publication bias, but further trim-and-fill analysis showed similar results.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, General & Internal
Di Chen, Gang Liu, Yurun Xie, Changsheng Chen, Zhihua Luo, Yujun Liu
Summary: This meta-analysis showed that continuing to take aspirin before TRUS-PB does not increase the risk of hematuria and hematospermia, but slightly increases the risk of rectal bleeding, which is self-limiting.
Review
Oncology
Adam Baker, Christiana Kartsonaki
Summary: This study investigated the associations between aspirin use and mortality in breast cancer patients. The results showed that only post-diagnostic aspirin use was significantly associated with lower breast-cancer-specific mortality.
Review
Medicine, General & Internal
Viranda H. Jayalath, Roderick Clark, Katherine Lajkosz, Rouhi Fazelzad, Neil E. Fleshner, Laurence H. Klotz, Robert J. Hamilton
Summary: This meta-analysis found that concurrent statin use was associated with reduced overall mortality and prostate cancer-specific mortality among men receiving androgen-ablative therapies for advanced prostate cancer.
Review
Biotechnology & Applied Microbiology
Bin Hao, Li Wei, Yusheng Cheng, Zhifang Ma, Jingyu Wang
Summary: Prostate cancer is the second most common cancer in men globally. Early diagnosis is crucial due to the lack of obvious symptoms in the early stage. Highly sensitive and precise diagnostic methods, as well as targeted therapy regimens, play key roles in the treatment of prostate cancer.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Medicine, General & Internal
Jiamin Liu, Fengxian Zheng, Meng Yang, Xiaoyong Wu, Aimin Liu
Summary: The meta-analysis indicated that aspirin use may be associated with lower breast cancer-specific death, all-cause death, and risk of recurrence/metastasis in patients with breast cancer.
Article
Nutrition & Dietetics
Wei Qi Loh, Jiyoung Youn, Wei Jie Seow
Summary: There is conflicting evidence regarding the association between vitamin E intake and prostate cancer risk. This meta-analysis found little evidence for a beneficial effect of vitamin E intake on prostate cancer risk overall, but suggests that supplements may have a protective effect in certain conditions.
Article
Medicine, General & Internal
David J. Fisher, Sarah Burdett, Claire Vale, Ian R. White, Jayne F. Tierney
Summary: The problem of overlap and duplication in background research is recognized in pairwise and network systematic reviews and meta-analyses. In this study, a scoping review was conducted to identify and examine duplicated network meta-analyses (NMAs) in the context of hormone-sensitive metastatic prostate cancer (mHSPC), where several novel therapies have emerged. The results revealed variations and inadequacies in review aims, eligibility criteria, statistical methodology, reporting, and inference across the identified reviews. The authors recommend publishing review protocols in advance, providing clarity on the aims or scope of the project, and presenting source data and results clearly for unbiased interpretation.
SYSTEMATIC REVIEWS
(2022)
Article
Public, Environmental & Occupational Health
Xianmin Wang, Yupeng Luo, Tingting Chen, Kui Zhang
Summary: The meta-analysis suggests that post-diagnosis, but not pre-diagnosis, low-dose aspirin use may reduce cancer-specific mortality, especially in the case of digestive tract cancers.
JOURNAL OF PUBLIC HEALTH
(2021)
Review
Oncology
Martyna Bakierzynska, Ms Carolyn Cullinane, Henry Paul Redmond, Mark Corrigan
Summary: This study found an association between aspirin intake and a reduced risk of breast cancer, especially with ingestion of more than 6 tablets per week. Aspirin had a more significant risk reduction in patients with estrogen receptor-positive breast cancer.
Review
Radiology, Nuclear Medicine & Medical Imaging
Laura Evangelista, Fabio Zattoni, Gianluca Cassarino, Paolo Artioli, Diego Cecchin, Fabrizio dal Moro, Pietro Zucchetta
Summary: This study summarized the diagnostic role of PET/MRI in patients with prostate cancer. The results showed that PET/MRI has high sensitivity for detecting primary PCa, especially when radiolabeled PSMA is used, and also has a high detection rate for recurrent disease.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Urology & Nephrology
Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin
Summary: The voting results from the 2021 Advanced Prostate Cancer Consensus Conference provide guidance for clinicians and patients in the management of advanced prostate cancer where evidence is scarce. However, treatment decisions should be individualized based on patient characteristics and current clinical evidence.
Review
Oncology
Lijuan Wang, Rongqi Zhang, Lili Yu, Jiarui Xiao, Xuan Zhou, Xinxuan Li, Peige Song, Xue Li
Summary: This study indicates that regular low-dose aspirin use can reduce the risk of colorectal, gastric, breast, and prostate cancer, but not lung cancer. High-frequency aspirin use may increase the risk of lung cancer, while high-dose use may increase the risk of prostate cancer. Further research is needed to confirm these findings and determine the minimum effective dose for cancer prevention.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Saimaitikari Abudoubari, Ke Bu, Yujie Mei, Abudukeyoumu Maimaitiyiming, Hengqing An, Ning Tao
Summary: This study explores the epidemiological trend and prognostic factors of prostate cancer patients through the latest cohort study and develops a new nomogram to predict the specific survival rate of patients. The results show significant changes in the incidence of prostate cancer with different characteristics, and the nomogram prediction model based on four factors has a high reference value in assessing patient-specific survival rate.
FRONTIERS IN ONCOLOGY
(2023)